Ignite Creation Date:
2024-05-06 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05027100
Status:
UNKNOWN
Last Update Posted:
2022-07-01
First Post:
2021-08-22
Brief Title:
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
Sponsor:
Haibo Zhang
Organization:
Guangzhou University of Traditional Chinese Medicine
Organization Data
Organization:
Guangzhou University of Traditional Chinese Medicine
Class:
OTHER
Study ID:
1020201227
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Haibo Zhang
Lead Sponsor Class:
OTHER
Responsible Party:
Haibo Zhang
Responsible Party Title:
Chief Physician
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Guangzhou University of Traditional Chinese Medicine
Old Name:
None
Old Organization:
None